Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR 1,128.90
-6.10 (-0.54%)
Oct 23, 2026, 1:40 PM IST
Zydus Lifesciences Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Zydus Lifesciences stock has a consensus rating of "Hold" and an average price target of ₹1,210. The average 1-year stock price forecast is 7.21% higher than the current stock price, while the lowest is ₹800.00 (-29.13%) and the highest is ₹1,457 (+29.11%).
Price Target: ₹1,210 (+7.21%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Aug 13, 2026.
Analyst Ratings
The average analyst rating for Zydus Lifesciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 8 | 8 | 8 |
| Buy | 9 | 9 | 9 | 7 | 7 | 7 |
| Hold | 10 | 10 | 10 | 8 | 9 | 8 |
| Sell | 2 | 2 | 2 | 4 | 3 | 3 |
| Strong Sell | 3 | 3 | 3 | 3 | 3 | 3 |
| Total | 30 | 30 | 31 | 30 | 30 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Hold Maintains ₹1,240 | Hold | Maintains | ₹1,240 | +9.84% | Aug 13, 2026 |
| Citi | Citi | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 5, 2026 |
Financial Forecast
Revenue This Year
317.71B
from 271.48B
Increased by 17.03%
Revenue Next Year
352.24B
from 317.71B
Increased by 10.87%
EPS This Year
40.36
from 54.00
Decreased by -25.26%
EPS Next Year
49.31
from 40.36
Increased by 22.19%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.